Business Description
Travere Therapeutics is a San Diego-based biopharmaceutical company focused on developing and commercializing treatments for people with rare kidney and metabolic diseases. Its marketed products include FILSPARI, a daily oral treatment for IgA Nephropathy, and Thiola, used to manage cystinuria, a genetic condition that leads to recurring kidney stones. The company also has two drugs in clinical development targeting focal segmental glomerulosclerosis and classical homocystinuria, a hereditary metabolic disorder. Formerly known as Retrophin Inc., the company rebranded as Travere Therapeutics in November 2020.
